Pharmacogenetic association study of 30 genes with phenobarbital drug response in epileptic dogs

Erin M. Kennerly, Youssef Idaghdhour, Natasha J. Olby, Karen R. Munana, Greg Gibson

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Epilepsy, with a prevalence as high as 6%, is the most common neurological disorder in dogs. Although several antiepileptic drugs are in common use, in one-third of all epileptic dogs, adequate seizure control is not achieved with a single medication, and hence a combinatorial drug treatment must be adopted. Exploration of the genetic mechanisms involved in drug response may provide better treatment options for epileptic patients. METHODS AND RESULTS: A custom Illumina BeadChip was designed for high throughput genotyping of 384 single nucleotide polymorphisms in 30 genes involved in drug metabolism, drug targeting, and drug transport. A case-control association study of 125 epileptic dogs identified five genes with suggestive association to phenobarbital drug response: KCNQ3, P=0.0003; SNC2A2, P=0.0008; EPOX HYD, P=0.0005; ABCC4, P=0.0091; and GABRA2, P=0.0130. These associations are not significant after adjustment for multiple comparisons, but on functional grounds may tag strong candidate genes. The study was powered to detect alleles with at least 3.5-fold additive increases in responsiveness. A combined area under the curve value of 0.74 from receiver operating curve analysis also provides suggestive support for their consideration as canine pharmacogenetic markers. CONCLUSION: Further replication and assessment of breed specificity is required before these markers can be considered as predictive of responsiveness to phenobarbital in dogs.

Original languageEnglish (US)
Pages (from-to)911-922
Number of pages12
JournalPharmacogenetics and Genomics
Volume19
Issue number12
DOIs
StatePublished - Dec 1 2009

Fingerprint

Phenobarbital
Dogs
Pharmaceutical Preparations
Genes
Pharmacogenetics
Drug Delivery Systems
Nervous System Diseases
Anticonvulsants
Area Under Curve
Single Nucleotide Polymorphism
Canidae
Case-Control Studies
Epilepsy
Seizures
Alleles
Pharmacogenomic Testing
Therapeutics

Keywords

  • Canine epilepsy
  • Drug response
  • Epoxide hydrolase
  • GABRA2
  • KCNQ3
  • Pharmacogenetics
  • Phenobarbital
  • SCN2A2

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Genetics(clinical)

Cite this

Pharmacogenetic association study of 30 genes with phenobarbital drug response in epileptic dogs. / Kennerly, Erin M.; Idaghdhour, Youssef; Olby, Natasha J.; Munana, Karen R.; Gibson, Greg.

In: Pharmacogenetics and Genomics, Vol. 19, No. 12, 01.12.2009, p. 911-922.

Research output: Contribution to journalArticle

Kennerly, Erin M. ; Idaghdhour, Youssef ; Olby, Natasha J. ; Munana, Karen R. ; Gibson, Greg. / Pharmacogenetic association study of 30 genes with phenobarbital drug response in epileptic dogs. In: Pharmacogenetics and Genomics. 2009 ; Vol. 19, No. 12. pp. 911-922.
@article{66162d64e65a4048be9dafaf368cdabf,
title = "Pharmacogenetic association study of 30 genes with phenobarbital drug response in epileptic dogs",
abstract = "BACKGROUND: Epilepsy, with a prevalence as high as 6{\%}, is the most common neurological disorder in dogs. Although several antiepileptic drugs are in common use, in one-third of all epileptic dogs, adequate seizure control is not achieved with a single medication, and hence a combinatorial drug treatment must be adopted. Exploration of the genetic mechanisms involved in drug response may provide better treatment options for epileptic patients. METHODS AND RESULTS: A custom Illumina BeadChip was designed for high throughput genotyping of 384 single nucleotide polymorphisms in 30 genes involved in drug metabolism, drug targeting, and drug transport. A case-control association study of 125 epileptic dogs identified five genes with suggestive association to phenobarbital drug response: KCNQ3, P=0.0003; SNC2A2, P=0.0008; EPOX HYD, P=0.0005; ABCC4, P=0.0091; and GABRA2, P=0.0130. These associations are not significant after adjustment for multiple comparisons, but on functional grounds may tag strong candidate genes. The study was powered to detect alleles with at least 3.5-fold additive increases in responsiveness. A combined area under the curve value of 0.74 from receiver operating curve analysis also provides suggestive support for their consideration as canine pharmacogenetic markers. CONCLUSION: Further replication and assessment of breed specificity is required before these markers can be considered as predictive of responsiveness to phenobarbital in dogs.",
keywords = "Canine epilepsy, Drug response, Epoxide hydrolase, GABRA2, KCNQ3, Pharmacogenetics, Phenobarbital, SCN2A2",
author = "Kennerly, {Erin M.} and Youssef Idaghdhour and Olby, {Natasha J.} and Munana, {Karen R.} and Greg Gibson",
year = "2009",
month = "12",
day = "1",
doi = "10.1097/FPC.0b013e3283307cba",
language = "English (US)",
volume = "19",
pages = "911--922",
journal = "Pharmacogenetics and Genomics",
issn = "1744-6872",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Pharmacogenetic association study of 30 genes with phenobarbital drug response in epileptic dogs

AU - Kennerly, Erin M.

AU - Idaghdhour, Youssef

AU - Olby, Natasha J.

AU - Munana, Karen R.

AU - Gibson, Greg

PY - 2009/12/1

Y1 - 2009/12/1

N2 - BACKGROUND: Epilepsy, with a prevalence as high as 6%, is the most common neurological disorder in dogs. Although several antiepileptic drugs are in common use, in one-third of all epileptic dogs, adequate seizure control is not achieved with a single medication, and hence a combinatorial drug treatment must be adopted. Exploration of the genetic mechanisms involved in drug response may provide better treatment options for epileptic patients. METHODS AND RESULTS: A custom Illumina BeadChip was designed for high throughput genotyping of 384 single nucleotide polymorphisms in 30 genes involved in drug metabolism, drug targeting, and drug transport. A case-control association study of 125 epileptic dogs identified five genes with suggestive association to phenobarbital drug response: KCNQ3, P=0.0003; SNC2A2, P=0.0008; EPOX HYD, P=0.0005; ABCC4, P=0.0091; and GABRA2, P=0.0130. These associations are not significant after adjustment for multiple comparisons, but on functional grounds may tag strong candidate genes. The study was powered to detect alleles with at least 3.5-fold additive increases in responsiveness. A combined area under the curve value of 0.74 from receiver operating curve analysis also provides suggestive support for their consideration as canine pharmacogenetic markers. CONCLUSION: Further replication and assessment of breed specificity is required before these markers can be considered as predictive of responsiveness to phenobarbital in dogs.

AB - BACKGROUND: Epilepsy, with a prevalence as high as 6%, is the most common neurological disorder in dogs. Although several antiepileptic drugs are in common use, in one-third of all epileptic dogs, adequate seizure control is not achieved with a single medication, and hence a combinatorial drug treatment must be adopted. Exploration of the genetic mechanisms involved in drug response may provide better treatment options for epileptic patients. METHODS AND RESULTS: A custom Illumina BeadChip was designed for high throughput genotyping of 384 single nucleotide polymorphisms in 30 genes involved in drug metabolism, drug targeting, and drug transport. A case-control association study of 125 epileptic dogs identified five genes with suggestive association to phenobarbital drug response: KCNQ3, P=0.0003; SNC2A2, P=0.0008; EPOX HYD, P=0.0005; ABCC4, P=0.0091; and GABRA2, P=0.0130. These associations are not significant after adjustment for multiple comparisons, but on functional grounds may tag strong candidate genes. The study was powered to detect alleles with at least 3.5-fold additive increases in responsiveness. A combined area under the curve value of 0.74 from receiver operating curve analysis also provides suggestive support for their consideration as canine pharmacogenetic markers. CONCLUSION: Further replication and assessment of breed specificity is required before these markers can be considered as predictive of responsiveness to phenobarbital in dogs.

KW - Canine epilepsy

KW - Drug response

KW - Epoxide hydrolase

KW - GABRA2

KW - KCNQ3

KW - Pharmacogenetics

KW - Phenobarbital

KW - SCN2A2

UR - http://www.scopus.com/inward/record.url?scp=73949160744&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73949160744&partnerID=8YFLogxK

U2 - 10.1097/FPC.0b013e3283307cba

DO - 10.1097/FPC.0b013e3283307cba

M3 - Article

C2 - 19841609

AN - SCOPUS:73949160744

VL - 19

SP - 911

EP - 922

JO - Pharmacogenetics and Genomics

JF - Pharmacogenetics and Genomics

SN - 1744-6872

IS - 12

ER -